Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 Shares

Kala Pharmaceuticals Inc (NASDAQ:KALA) major shareholder Orbimed Advisors Llc purchased 240,484 shares of the business’s stock in a transaction on Friday, January 12th. The stock was acquired at an average cost of $13.28 per share, with a total value of $3,193,627.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Wednesday, January 10th, Orbimed Advisors Llc purchased 170,338 shares of Kala Pharmaceuticals stock. The stock was acquired at an average cost of $12.83 per share, with a total value of $2,185,436.54.

Shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) traded up $1.75 during midday trading on Friday, reaching $15.60. 386,757 shares of the company’s stock were exchanged, compared to its average volume of 389,052. Kala Pharmaceuticals Inc has a 52 week low of $11.81 and a 52 week high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. The firm has a market cap of $377.94 and a P/E ratio of -8.57.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.14). sell-side analysts anticipate that Kala Pharmaceuticals Inc will post -2.22 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $54,251,000. Caxton Corp purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $12,430,000. Victory Capital Management Inc. purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $12,414,000. OxFORD Asset Management LLP purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $4,374,000. Finally, JPMorgan Chase & Co. purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $4,037,000. 62.96% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on the stock. Wells Fargo & Co reissued a “buy” rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. BidaskClub raised shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 29th. Wedbush reissued an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a report on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Zacks Investment Research downgraded shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Kala Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $36.80.

TRADEMARK VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/12/kala-pharmaceuticals-inc-kala-major-shareholder-orbimed-advisors-llc-purchases-240484-shares.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply